Allison Gillespie’s Post

We are delighted to be exhibiting and presenting at the World EPA Congress this week. If you are attending, come and bob by our stand 86 for a coffee and chat to discuss your pricing and access challenges. If you are not attending, why not subscribe to our newsletter where you can catch up on our insights #hta #epacongress #pharmaceuticals #conferences #euhta

Group practices, health systems, and health care corporations are eligible for a Pinnacle Award under category 2. This category recognizes a significant scientific contribution and/or quality improvement project conducted in one or more of the following areas: ·       Fostering the role of multidisciplinary health care teams in improving medication persistence and adherence. ·       Adoption of, or adherence to, national treatment guidelines. ·       Preventing and eliminating adverse drug events. ·       Developing innovations and improvement techniques to enhance medication use. ·       Innovation in the management of drug therapy while significantly improving patient outcomes. Anyone can serve as the nominator for a Pinnacle Award, including self-nominations, and the nominee is not required to be a pharmacist or APhA member. Apply here:https://ow.ly/gYoV50S8u0k Learn more about the Pinnacle Awards here:https://ow.ly/rPwY50S8u0j Nominations will close June 30 at 11:59 pm ET. Support for the 2024 Pinnacle Awards Program is provided by Merck.

Have you signed up for tomorrow's 60-minute masterclass, Market Access NHS England In conversation with Neil Grubert? Key Learning Objectives: 🗣️ What does Neil think will be the key drivers of access success for the remainder of 2024 and beyond? 🗣️ What access barriers will you need to overcome ? 🗣️ What is the outlook for access and how does pharma and medtech need to respond post the General Election? Can't make it tomorrow? Register and we'll send you a link to the recording so you can watch it on demand in your own time. #nhs #lsaa #lifesciences #pharma #medtech #marketaccess #HealthcareStrategy #UKPolitics #AccessBarriers #Election2024 #HealthPolicy #StakeholderEngagement #HealthcareMasterclass LSAA Members register here: https://lnkd.in/edXyisCJ 🎙️Connect with us! Speaker: Neil Grubert Host: Ian Chamberlain To see our other masterclasses, go to our website: https://lnkd.in/eVJWfGih

4 years later, an update on DiGA!   It has been running up for 4 years, and at time of writing, there are 55 listed DiGAs (over a quarter of submitted applications). Among them, 20 are provisionally listed and 35 are permanently listed.   💰 Average reimbursement per prescription is 302€ 🔶 Provisional listing price tag : [200€ – 700€] ✔ Permanent listing price tag: 50% of provisional – with a median value at 221€ 📈 Increasing volume per reporting period (12mo), from 41,000 to 124,000 to 209,000 🔎 Uniform preference for RCT as a standard for clinical validation   Setting standard reimbursement frameworks for new approaches is challenging, especially in an agitated market like digital health. However, recent efforts such as DigiG Act (Germany), PECAN launch (France), revamping of mHealth framework (Belgium) and Access to PDT Act (United States) are signals of renewed energy around this matter.   via Marko Kuisma and JMIR publication from Moritz Göldner and Sara G. 📌 Check-out the sources in first comment!   #digitalhealth #marketaccess #diga

🌐 Join us for an exclusive CME Event for NMA Members! 🏥✨ On Jan 16, 2024, at 9:00 PM ET, our Health Policy Committee presents a crucial 340B Panel Discussion. 💊 Explore the ins and outs of the 340B drug pricing program, a cornerstone of American healthcare since the '90s. 🏛️🩺 Understand its impact on safety net hospitals and community care organizations, providing reduced-cost access to essential prescription drugs. 🔍 However, concerns about regulation and fund misappropriation have arisen. It's time for NMA members to stay ahead in healthcare trends! 📚 🗓️ Save the date for an hour of insightful discussion led by topical experts. Gain the knowledge needed to advocate for proper program oversight. 🌟💡 📌 Where: Zoom Webinar Event ⏰ When: Jan 16, 2024, 9:00 PM ET 🔗 RSVP: https://bit.ly/48rrKEG Stay informed, engaged, and empowered! 🌐 #NMAEvents #HealthcareTrends #340BPanel #CMEEvent #HealthPolicy #MedicalEducation #NMAInsights

We are happy to share the success of today’s event, ‘Consultation Conference: EU guidance on Public Procurement of Medicines’, which brought together over 300 stakeholders from the broader NCAPR (National Competent Authorities on Pricing and Reimbursement and Public Healthcare Payers) group and relevant experts! 🚀 Following the ‘Commission Communication on Addressing Shortages in the EU’, PredictBy is now responsible of leading an expert group on the development of EU guidance for #DGSante.  The guidance will provide insights on the use and implementation of good practices in the public procurement of medicines, focusing on enhancing security of supply. The aim of the conference, led by Marina Rodés Sánchez and supported by Anna Jansana, was to present the draft document and collect overarching feedback. Building on the suggestions collected, we hope the upcoming guidance will further support Member States and procurers in their procurement practices. A huge THANK YOU to everyone who attended, cecoforma events & communication for organising, and to all the MS specialists who are contributing to the development of this guidance, in particular Maeve Hynes, Ismail Khdeir, Frank Wienands, Eirikur Arnar Sverrisson (Gretarsson) and Maximilian Salcher-Konrad for your great presentations during the Conference! 🎤👏 Stay tuned for future events and reports led by PredictBy, and follow us for the latest updates and opportunities to get involved. #consultationconference #ppm #procurement #medicinalproducts #guidancedocument #securityofsupply #healthpolicy  This conference was for a project conducted as part of HADEA/2022/OP/0012 - Multiple Framework Contracts in cascade for support services to manage expert groups in the field of health 2023-2025, where we are collaborating with Intellera, CECOFORMA, and Empirica.

[CTIS: launch of the new version of the CTIS website and revised transparency rules 🌐🔍 ]   📢 Get ready for June 18, 2024! This is the date when the revised transparency rules for the Clinical Trials Information System (CTIS) will become applicable.   𝗧𝗵𝗲𝘀𝗲 𝘂𝗽𝗱𝗮𝘁𝗲𝗱 𝗿𝘂𝗹𝗲𝘀 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗯𝗼𝘁𝗵 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝘀𝗽𝗼𝗻𝘀𝗼𝗿𝘀: 🔹 Patients benefit from them because key clinical trial information is published early. 🔹 Process simplifications benefit sponsors who have to protect Commercially Confidential Info (CCI) and personal data. They will, however, have to adapt their processes to align with those new rules.   What do you think of this new balance in the rules? ➡️ DM us if you would like to discuss how we can help you navigate CTIS and your European clinical trial in general.   #clinicaltrials #clinicaltrialsinformationsystem #clinicaldata

At UVDI, we’re dedicated to advancing evidence-based medicine, enhancing ease-of-use, and ensuring responsible capital deployment within hospitals. That’s why we’re excited to announce our participation in the upcoming Association of Healthcare Value Analysis Professionals (AHVAP) Conference! Supporting value analysis professionals is at the heart of what we do and our partnerships are incredibly important. No one articulates the mission and mandate of value analysis better than AHVAP: “Using evidence-based data, professional experience, and an understanding of the cost/quality continuum, Value Analysis professionals guide clinical and other providers in the product, services and technology review and selection process and assist with the resolution of quality concerns.” This conference is a fantastic platform to highlight the crucial role of value analysis professionals, who bridge the gap between clinical needs and operational efficiency. We proudly support AHVAP and their efforts! Together, we can drive innovation and excellence in healthcare. See you at the conference! 🙌 #AHVAP2024 #ValueAnalysis #EvidenceBasedMedicine #HealthcareInnovation #ProfessionalDevelopment #SupportAHVAP

Looking forward to an insightful panel discussion with LeeAnn Ali

Prepare your FHIR compliance roadmap. Get an overview of the relevant Rules and Implementation Guides. Download your copy now!🔥 #FHIR #HealthcareRegulations #ONC #CMS #HealthTech